Stocktoria
Lexeo Therapeutics, Inc. LXEO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-11-03
Lexeo Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | $654,000 |
| R&D expense | $63.8M | $74.1M | $53.1M | $49.2M |
| Operating income | -$109.3M | -$105.8M | -$68.5M | -$60.5M |
| Interest expense | — | — | $205,000 | $91,000 |
| Income tax | $0 | $0 | — | — |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| EPS (diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M | -$54.6M |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M | -$55.2M |
| Cash & equivalents | $63.0M | $35.0M | $121.5M | $77.3M |
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M |
| Total liabilities | $22.0M | $30.1M | $26.3M | $25.0M |
| Shareholders' equity | $246.7M | $116.8M | $113.5M | -$113.0M |
Source: SEC EDGAR filings · CIK 0001907108 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.